Latest Conference Articles

January 19th 2019, 3:19am

Gastrointestinal Cancers Symposium (ASCO GI)

Overall survival in metastatic gastric/gastroesophageal junction cancer improved significantly in patients who received the combination therapy TAS-102, irrespective of prior gastrectomy.

January 19th 2019, 3:11am

SGO Winter Meeting

Katherine Kurnit, MD, OBGYN oncology fellow at the University of Texas MD Anderson Cancer Center, compares the benefit of gastrointestinal-based versus gynecologic-based adjuvant chemotherapy regimens in patients with mucinous ovarian cancer.

January 19th 2019, 12:44am

SGO Winter Meeting

Results from a recent retrospective study indicate that treatment with a gastrointestinal-based adjuvant chemotherapy regimen may be more beneficial than that of a gynecologic-based one in patients with mucinous ovarian cancer.

January 19th 2019, 12:41am

Gastrointestinal Cancers Symposium (ASCO GI)

Rachna T. Shroff, MD, MS, discusses the importance of molecular profiling upon diagnosis in patients with cholangiocarcinoma.

January 19th 2019, 12:02am

Gastrointestinal Cancers Symposium (ASCO GI)

Marcus Noel, MD, discusses the data of SM-88 and how it will impact the treatment of patients with metastatic pancreatic cancer.

January 18th 2019, 11:59pm

Gastrointestinal Cancers Symposium (ASCO GI)

The combination of nivolumab and ramucirumab has activity in patients with previously treated advanced gastric adenocarcinoma, investigators reported at the 2019 Gastrointestinal Cancers Symposium.

January 18th 2019, 11:58pm

Gastrointestinal Cancers Symposium (ASCO GI)

Allyson J. Ocean, MD, discusses her experiences with SM-88 in patients with metastatic pancreatic cancer.

January 18th 2019, 11:49pm

SGO Winter Meeting

Genomic testing to guide treatment decisions for women with ovarian cancer is in its early days. However, as more platforms become commercially available, physicians will need to understand the similarities and differences between tests.

January 18th 2019, 11:47pm

Gastrointestinal Cancers Symposium (ASCO GI)

Two-thirds of patients with untreated metastatic HER2-positive esophagogastric adenocarcinoma remained free of disease progression at 6 months with a combination of pembrolizumab, trastuzumab, and chemotherapy.

January 18th 2019, 10:26am

SGO Winter Meeting

Eleftheria Kalogera, MD, MSc, instructor in Obstetrics and Gynecology, fellow in Gynecologic Oncology, in the department of Obstetrics and Gynecology, at Mayo Clinic College of Medicine, discusses the controversial topic of bowel preparation following minimally invasive or open hysterectomies.

January 18th 2019, 9:26am

SGO Winter Meeting

Shannon N. Westin, MD, MPH, associate professor, The University of Texas MD Anderson Cancer Center, discusses advances made with PARP inhibitors in the ovarian cancer treatment paradigm.

January 18th 2019, 4:59am

Gastrointestinal Cancers Symposium (ASCO GI)

Pembrolizumab was found to reduce the risk of death by 31% in patients with PD-L1–positive advanced or metastatic esophageal or esophageal junction carcinoma who progressed on standard therapy.

January 18th 2019, 2:33am

SGO Winter Meeting

Several ongoing trials are examining combinations of PARP inhibitors and immunotherapy agents as frontline maintenance for patients with ovarian cancer.

December 11th 2018, 8:31pm

ASH Annual Meeting and Exposition

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses induction therapy with bendamustine and rituximab (Rituxan; BR) in the treatment of patients with mantle cell lymphoma (MCL).

December 11th 2018, 8:29pm

ASH Annual Meeting and Exposition

Jordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses the potential for chimeric antigen receptor T-cell therapy in the treatment of chronic lymphocytic leukemia.

December 10th 2018, 9:39pm

San Antonio Breast Cancer Symposium

Chemotherapy for breast cancer caused significantly more acute symptoms as compared with endocrine therapy, although the adverse effects of endocrine therapy increased over time.

December 8th 2018, 4:01am

San Antonio Breast Cancer Symposium

Chimeric antigen receptor T cells targeting the tyrosine kinase receptor ROR1 can be transferred into patients safely and the cells expand in vivo.

December 8th 2018, 1:07am

San Antonio Breast Cancer Symposium

Early-stage breast cancer survivors who completed a telephone-based lifestyle intervention program lost weight and tended to have higher rates of disease-free survival.

December 8th 2018, 12:10am

San Antonio Breast Cancer Symposium

The combination of olaparib and durvalumab in patients with HER2-negative metastatic breast cancer with germline BRCA mutations is well tolerated and has promising activity, especially in earlier settings.

December 8th 2018, 12:03am

San Antonio Breast Cancer Symposium

Younger patients with breast cancer who underwent lumpectomy had better quality of life than women who had a mastectomy.